SWOG clinical trial number
S0002
Smoking Cessation Intervention (Including Bupropion-Zyban Versus Placebo) for Completely Resected Stage I and Stage II Non-Small Cell Lung Cancer Survivors Who Are Currently Smokers, Phase III
Closed
Phase
Accrual
2%
Research committees
Lung Cancer
Treatment
Bupropion
Nicotine Patch
Eligibility Criteria Expand/Collapse
Pt must be dx'd w/Stage I or II NSCLC and be free of recurrent or progressive disease. Pt must have complete resection of all disease. Pt may rec concurrent adj chemo and/or RT or may have rec'd neoadj therapy. Pt must have a Zubrod PS of 0-2. Pt must be a current smoker as defined in Section 5.5 of the protocol. Pt must establish a quit date prior to reg which falls w/in 30 days after reg. Pts in the immediate post-infarction period, pts w/uncontrolled arrhythmias and pts w/unstable angina are not eligible. If pt has hypertension, it must be adequately controlled. Pt must not have a hx of seizures or eating disorders. Pt must not be taking any concomitant medications that lower seizure threshold. Pt must be able to read, speak and understand English. Pt must not have a current psychiatric dx that would interfere w/ability to participate in the intervention. Pt must not be rec'd or planning to rec any other medications that contain bupropion, any form of nicotine replacement therapy, or any other antidepressant or antipsychotic medication. There must be no known drug-drug interaction between nicotine and/or bupropion w/ pt's current or planned medications. Pt must have completed baseline packet of questionnaires. Pt must be willing to have saliva testing for cotinine levels. Pt must be offered participation on the correlative studies outlined in Section 15.1.
CANCER CONTROL CREDIT: 0.7
TREATMENT CREDIT: 0.0
CANCER CONTROL CREDIT: 0.7
TREATMENT CREDIT: 0.0
Other Clinical Trials
SWOG Clinical Trial Number
S2302
PRAGMATICA - LUNG: A PROSPECTIVE RANDOMIZED STUDY OF RAMUCIRUMAB (LY3009806; NSC 749128) PLUS PEMBROLIZUMAB (MK-3475; NSC 776864) VERSUS STANDARD OF CARE FOR PARTICIPANTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER
Research Committee(s)
Lung Cancer
Activated
03/06/2023
Accrual
95%
Open
Phase
SWOG Clinical Trial Number
A082002
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Research Committee(s)
Lung Cancer
Activated
12/21/2021
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-LU007
RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Research Committee(s)
Lung Cancer
Activated
08/17/2020
Open